GH Research plc has announced results from a double-blind, placebo-controlled clinical trial evaluating GH001, an investigational treatment for patients with treatment-resistant depression (TRD). The study, which included a 7-day randomized phase and a 6-month open-label extension, assessed the safety and incidence of suicidal ideation and behavior in patients receiving individualized dosing regimens of GH001 or placebo. Findings demonstrated that GH001 was not associated with treatment-emergent events of suicidal ideation with intent or suicidal behavior. The trial also reported that the number of patients experiencing suicidal ideation decreased over the course of the study, and no serious adverse events related to suicide risk were observed. These results were presented by a team of international researchers, including Sanjay J. Mathew of Texas A&M College of Medicine.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-038374), on October 17, 2025, and is solely responsible for the information contained therein.
Comments